{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Progressive&page=15",
    "query": {
      "intervention": "Progressive",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 2386,
    "total_pages": 239,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Progressive&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Progressive&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T00:39:30.945Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01342757",
      "title": "Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Adult Glioblastoma",
        "Depression",
        "Recurrent Adult Brain Tumor"
      ],
      "interventions": [
        {
          "name": "vorinostat",
          "type": "DRUG"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "magnetic resonance spectroscopic imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "survey administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2010-12",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2018-01-29",
      "last_synced_at": "2026-10-24T00:39:30.945Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01342757"
    },
    {
      "nct_id": "NCT00508456",
      "title": "Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Temodar (Temozolomide)",
          "type": "DRUG"
        },
        {
          "name": "Hominex-2",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 18,
      "start_date": "2004-08",
      "completion_date": "2008-11",
      "has_results": false,
      "last_update_posted_date": "2012-01-16",
      "last_synced_at": "2026-10-24T00:39:30.945Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00508456"
    },
    {
      "nct_id": "NCT01318902",
      "title": "Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Light-Chain Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Ixazomib",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2011-04-27",
      "completion_date": "2018-11-13",
      "has_results": true,
      "last_update_posted_date": "2020-04-01",
      "last_synced_at": "2026-10-24T00:39:30.945Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Detroit, Michigan • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01318902"
    },
    {
      "nct_id": "NCT00227656",
      "title": "Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "PEG-interferon alfa-2a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2005-09",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2012-12-11",
      "last_synced_at": "2026-10-24T00:39:30.945Z",
      "location_count": 4,
      "location_summary": "Wichita, Kansas • Grand Rapids, Michigan • Springfield, Missouri + 1 more",
      "locations": [
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00227656"
    },
    {
      "nct_id": "NCT01338857",
      "title": "Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "neurofibromatosis1 (NF1)",
        "Recurrent or Progressive Optic Pathway Gliomas (OPG)",
        "Recurrent or Progressive Low-grade Glioma"
      ],
      "interventions": [
        {
          "name": "Sorafenib (Nexavar)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2011-04",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2017-02-17",
      "last_synced_at": "2026-10-24T00:39:30.945Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01338857"
    },
    {
      "nct_id": "NCT00924651",
      "title": "Exercise in Lessening Fatigue Caused by Cancer in Patients Undergoing Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fatigue",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "exercise",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Gary Morrow",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "21 Years to 120 Years"
      },
      "enrollment_count": 693,
      "start_date": "2009-09",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2017-08-08",
      "last_synced_at": "2026-10-24T00:39:30.945Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00924651"
    },
    {
      "nct_id": "NCT01824901",
      "title": "Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Non-small Cell Lung Cancer",
        "Squamous Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "AZD4547",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "25 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2014-01-15",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2023-06-29",
      "last_synced_at": "2026-10-24T00:39:30.945Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Brookline",
          "state": "Massachusetts"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01824901"
    },
    {
      "nct_id": "NCT05488951",
      "title": "The Influence of the Otago Exercise Program on Executive Function Among People Living With Mild to Moderate Dementia",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dementia"
      ],
      "interventions": [
        {
          "name": "Otago Exercise Program",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Augusta University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2022-07-01",
      "completion_date": "2023-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-01-31",
      "last_synced_at": "2026-10-24T00:39:30.945Z",
      "location_count": 1,
      "location_summary": "Augusta, Georgia",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05488951"
    },
    {
      "nct_id": "NCT02270931",
      "title": "A Prospective Longitudinal Breast Cancer Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "CA 15-3 Assay",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Fujirebio Diagnostics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2014-05",
      "completion_date": "2021-06-30",
      "has_results": false,
      "last_update_posted_date": "2021-08-17",
      "last_synced_at": "2026-10-24T00:39:30.945Z",
      "location_count": 3,
      "location_summary": "Boca Raton, Florida • Fort Lauderdale, Florida • Wilmington, North Carolina",
      "locations": [
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Wilmington",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02270931"
    },
    {
      "nct_id": "NCT02114229",
      "title": "Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Rhabdoid Tumor",
        "Atypical Teratoid Rhabdoid Tumor"
      ],
      "interventions": [
        {
          "name": "alisertib",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "topotecan",
          "type": "DRUG"
        },
        {
          "name": "vincristine",
          "type": "DRUG"
        },
        {
          "name": "Surgical resection",
          "type": "PROCEDURE"
        },
        {
          "name": "Radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 125,
      "start_date": "2014-05-14",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-24T00:39:30.945Z",
      "location_count": 9,
      "location_summary": "Palo Alto, California • San Diego, California • Aurora, Colorado + 6 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02114229"
    }
  ]
}